Board of Trustees of The Leland Stanford Junior University’s Fate Therapeutics FATE Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio FATE Stock Details FATE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-291,067	Closed	-$908K	–	23
2016 Q3	$908K	Hold	291,067	–	–	0.1%	11
2016 Q2	$495K	Buy	291,067 +5,114	+2%	+$9.27K	0.07%	9
2016 Q1	$515K	Sell	285,953 -5,114	-2%	-$10.5K	0.07%	10
2015 Q4	$981K	Hold	291,067	–	–	0.18%	7
2015 Q3	$1.55M	Hold	291,067	–	–	0.39%	7
2015 Q2	$1.88M	Hold	291,067	–	–	0.82%	12
2015 Q1	$1.42M	Hold	291,067	–	–	1.41%	16
2014 Q4	$1.46M	Buy	291,067 +67	+0%	+$296	0.42%	16
2014 Q3	$1.48M	Sell	291,000 -1,567	-0.5%	-$9.07K	0.76%	15
2014 Q2	$1.85M	Sell	292,567 -10,971	-4%	-$77.3K	1.74%	5
2014 Q1	$2.96M	Hold	303,538	–	–	1.12%	38
2013 Q4	$1.91M	Buy	+303,538	New	+$1.91M	1.19%	3

Other funds holding FATE

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Board of Trustees of The Leland Stanford Junior University's FATE Position: Q4 2016 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Fate Therapeutics (FATE) in Q4 2016, closing a stake of 291,067 shares — an estimated $908K sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in FATE in Q4 2013 and held it in 12 quarters. The position peaked at $2.96M in Q1 2014. 37 funds tracked by Wall St. Rank hold FATE as of Q4 2016.

Board of Trustees of The Leland Stanford Junior University reported no remaining Fate Therapeutics position as of Q4 2016 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 291,067 Fate Therapeutics shares in Q4 2016, an estimated $908K.
Board of Trustees of The Leland Stanford Junior University first reported a position in Fate Therapeutics in Q4 2013 and held it in 12 quarters.
Board of Trustees of The Leland Stanford Junior University's Fate Therapeutics position peaked at $2.96M in Q1 2014.
37 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2016.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q4 2016, filed 10 Feb 2017.